Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...

Its HPV vaccine called GARDASIL is another popular treatment and has led to weak share price performance due to problems in China. Merck & Co., Inc. (NYSE:MRK)’s Chinese distributor has limited ...

Merck & Co., Inc. operates as a healthcare company ... and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta ...

Kennedy for years has earned referral fees from Wisner Baum, a Los Angeles personal injury law firm that is currently suing Merck ... human papillomavirus (HPV), Gardasil, according to financial ...